CellAegis Devices Inc., a Toronto based developer of proprietary, automated, noninvasive autoRIC Device for Remote Ischemic Conditioning (RIC), has officially announced US $9.5 million Series C led by CTI Life Sciences Fund, co-led by a U.S. based strategic investor – ##Subscriber – please login to see the name##. Other investors included MaRS Catalyst Fund, Broadview Ventures, and strategic family offices.
Dr. Shermaine Tilley, Managing Partner in CTI Life Sciences Fund, and an appointee from the US Strategic investor have joined CellAegis’ board of Directors. Christopher Colecchi, from Broadview Ventures, will also serve as a director.
The newly reconstituted board also includes ##subscriber ONLY content, please login to see full content##
“We are ready to advance clinical commercialization of autoRIC Device in the EU and Canada, complete the FDA trial and gain approval to open the US market,” said Rocky Ganske, CEO of CellAegis Devices. “This financing adds the experience of seasoned Canadian and U.S. medical technology investors, and demonstrates the support of our existing investors.”
“CTI Life Sciences Fund is enthusiastic to provide capital to CellAegis at this important juncture in the company’s development. The autoRIC Device shows promise in significantly improving outcomes in cardiovascular and other organ systems following ischemic events such as heart attacks, and we look forward to facilitating its clinical testing and regulatory submission for the U.S. market,” said Dr. Tilley.
photo credit: CellAegis Devices
Ted is the architect of CVCA infobase, and is the architect of CPE Analytics' Financings.ca, Canada's most sophisticated and advanced all private capital and public market financing database.
- ServiceNow paid US $230M for CDPQ and DCVC backed Element AI - January 14, 2021
- Former PayBright shareholders to reap rewards from Affirm IPO - January 10, 2021
- Hg acquires majoriy stake in Prophix for £190M - January 6, 2021
